Clinical Trials Logo

Liver Diseases clinical trials

View clinical trials related to Liver Diseases.

Filter by:

NCT ID: NCT03589430 Not yet recruiting - Clinical trials for Haemostasis Imbalance in Chronic Liver Disease

Haemostatic Imbalance in Patients With Chronic Liver Disease

Start date: September 1, 2018
Phase:
Study type: Observational

To assess the level of protein C, S ,antithrombin in patients with liver cirrhosis To correlate the level of these parameters with the degree of liver cirrhosis To correlate the level of procoagulants with the level of anticoagulant proteins in liver cirrhosis

NCT ID: NCT03587363 Not yet recruiting - Hepatic Impairment Clinical Trials

A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Erdafitinib

Start date: July 9, 2018
Phase: Phase 1
Study type: Interventional

The primary purpose of the study is to characterize the single dose pharmacokinetic of erdafitinib in participants with impaired hepatic function relative to participants with normal hepatic function.

NCT ID: NCT03587298 Recruiting - NAFLD Clinical Trials

Use of Shear Wave Elastography to Assess Non-alcoholic Fatty Liver Disease (NAFLD)

NAFLD
Start date: July 2018
Phase:
Study type: Observational

The aim of this study is to test a non-invasive imaging technique to reliably diagnose NAFLD in children and adolescents with obesity and assess the degree of fibrosis.

NCT ID: NCT03584646 Recruiting - Liver Diseases Clinical Trials

Prehabilitation Intervention to Maximize Early Recovery (PRIMER) in Liver Transplantation

PRIMER
Start date: February 28, 2018
Phase: N/A
Study type: Interventional

This is a single center, 2-arm, patient-randomized study evaluating the feasibility and potential efficacy of the PRIMER intervention in improving physical function and reducing frailty in adult Liver Transplant candidates. The intervention will consist of a patient-tailored prehabilitation program designed to reduce frailty, improve physical function and nutritional status, and optimize pre- and post-transplant outcomes.

NCT ID: NCT03583996 Not yet recruiting - Clinical trials for Chronic Liver Disease

The SHUNT-V Study for Varices

Start date: July 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is to validate the Disease Severity Index (DSI) from the HepQuant SHUNT Liver Diagnostic Kit (Test) for likelihood of large esophageal varices.

NCT ID: NCT03583437 Not yet recruiting - Clinical trials for NAFLD - Nonalcoholic Fatty Liver Disease

Hepatic and Cardiac Metabolic Flexibility in Obese With NAFLD.

Start date: September 2018
Phase:
Study type: Observational [Patient Registry]

Non-alcoholic fatty liver disease (NAFLD) covers a spectrum from reversible hepatic steatosis to inflammation and fibrosis termed steatohepatitis (NASH) and cirrhosis. New evidence indicates that NAFLD is associated with development of heart failure, abnormal ventricular glucose and fatty acid (FA) utilisation and cardiosteatosis. The mechanisms behind cardiac involvement and the progression from NAFLD to NASH are poorly understood but must include altered cardiac and intrahepatic lipid handling. In collaboration with renowned research groups from Oxford, Mayo Clinic and Copenhagen investigators plan comprehensive kinetic studies of heart and liver FA uptake and oxidation, ventricular function and substrate utilisation, and hepatic triglyceride (TG) secretion in order to assess mechanisms governing cardiac and hepatic lipid and glucose trafficking in subjects with NAFLD and NASH and the relationship with heart function. In addition, the investigators will assess skeletal muscle and adipose tissue enzyme activities, gene expression and protein concentrations in these subjects to define mechanisms involved in the cross-talk between heart, liver, muscle and adipose tissues. Investigators will address these questions using innovative tracer techniques (11Cpalmitate, 11C acetate, 18FDG glucose PET tracers and TG tracers) in combination with hepatic vein catherisation to study cardiac and liver substrate trafficking, as well as NMR spectroscopy, echocardiography, muscle and fat biopsies in combination with state-of-the art muscle and adipose tissue enzyme kinetics, gene- and protein expression. Effects of acute exercise will be assessed. The overarching goals are to define abnormalities and differences between NAFLD and NASH in hepatic lipid (FA and TG) metabolism and to assess the effect of exercise on both hepatic, cardiac and adipose and skeletal muscle lipid and substrate utilisation.

NCT ID: NCT03580629 Not yet recruiting - Clinical trials for End Stage Liver Disease

Pilot Study of the Liver Live Donor Champion Program

LLDC
Start date: July 2018
Phase: N/A
Study type: Interventional

In this pilot study, investigators plan to enroll liver transplant candidates and a "Live Donor Champion" for an abridged two- or three-month program that provides education and advocacy training in order to expand access to live donor liver transplantation. Investigators have created two versions of the same program and based on feedback from participants and staff, investigators aim to analyze the efficacy of the Liver Liver Donor Champion program on this patient population.

NCT ID: NCT03572465 Not yet recruiting - Clinical trials for Nonalcoholic Fatty Liver Disease (NAFLD)

Quantitative Ultrasound Techniques for Diagnosis of Nonalcoholic Steatohepatitis

QUS in NASH
Start date: August 1, 2018
Phase:
Study type: Observational

Nonalcoholic fatty liver disease is the most common liver disease in Western countries, due in large part to its association with type 2 diabetes and obesity. The more advanced form of this disease is known as nonalcoholic steatohepatitis (NASH). If left untreated, NASH can evolve to cirrhosis, the late stage of fibrosis. Once cirrhosis is established, patients are at increased risk of developing gastrointestinal bleeding, liver cancer and liver failure that may require transplantation. A liver biopsy is currently needed to diagnose the severity of fatty liver disease but this is usually not indicated in asymptomatic patients. This procedure requires the insertion of a needle inside the liver to remove a small piece of tissue for examination under microscope. Liver biopsy is an invasive procedure with a small risk of major complications such as bleeding in 0.5% of cases. It is also affected by sub-optimal sampling leading to diagnostic errors Ultrasound is optimum for screening patients with or without symptoms because it is a safe and widely available technology to scan the whole liver. Members of our team have developed Advanced ultrasound techniques that provide unique information not possible with state-of-the-art techniques. Unlike liver biopsy, these techniques would be applicable even in asymptomatic patients because it is non-invasive. This research proposal proposes a novel approach for diagnosis of NASH and will be the first study to measure individual components of NASH (fat, inflammation and fibrosis) with quantitative ultrasound (QUS) scores. This study is timely because NASH is the second leading cause of liver transplantation in North America and is predicted to become the leading indication in the near future.

NCT ID: NCT03569826 Recruiting - Clinical trials for Autoimmune Hepatitis

Canadian Network for Autoimmune Liver Disease

CaNAL
Start date: February 7, 2018
Phase:
Study type: Observational [Patient Registry]

This study is a longitudinal observational cohort study of patients diagnosed with Primary Biliary Cholangitis (PBC), Autoimmune Hepatitis (AIH) or overlap syndrome.This study creates a nationwide registry and network focusing on high quality long-term follow-up of individual patient data from major Canadian centers.

NCT ID: NCT03566173 Completed - Acute Pancreatitis Clinical Trials

Lack of Independent Relationship Between Nonalcoholic Fatty Liver Disease and Acute Pancreatitis

Start date: March 10, 2018
Phase:
Study type: Observational [Patient Registry]

The early evaluation of AP severity are vital. Previous studies have shown non-alcoholic fatty liver disease (NAFLD) is associated with severity of acute pancreatitis (AP). This study is aimed to investigate the relationship between NAFLD and AP severity.